TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS
Osteoporosis - a disease witch relates to both women and men, present a growing global problem due to the aging population. Low bone mass and a deterioration microarchitecture are characteristic features of osteoporosis that can lead to fractures, related pain, physical disability, poor quality of l...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
E A Pigarova [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch ; Russisch |
| Erschienen: |
2015 |
|---|
| Übergeordnetes Werk: |
In: Остеопороз и остеопатии - Endocrinology Research Centre, 2018, 18(2015), 1, Seite 41-42 |
|---|---|
| Übergeordnetes Werk: |
volume:18 ; year:2015 ; number:1 ; pages:41-42 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.14341/osteo2015141-42 |
|---|
| Katalog-ID: |
DOAJ003016064 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ003016064 | ||
| 003 | DE-627 | ||
| 005 | 20230309172851.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14341/osteo2015141-42 |2 doi | |
| 035 | |a (DE-627)DOAJ003016064 | ||
| 035 | |a (DE-599)DOAJda467b388c51405a9e05cf51e03dd59c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a rus | ||
| 050 | 0 | |a RZ301-397.5 | |
| 100 | 0 | |a E A Pigarova |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Osteoporosis - a disease witch relates to both women and men, present a growing global problem due to the aging population. Low bone mass and a deterioration microarchitecture are characteristic features of osteoporosis that can lead to fractures, related pain, physical disability, poor quality of life, increased mortality, and high costs of medical care. Teriparatide (recombinant human parathyroid hormone [rhPTH (1-34), Forsteo], which appeared more than a decade ago, is the only one registered in the Russian Federation anabolic treatment for osteoporosis, which increases the density and strength of bone. Initially, it was approved for the treatment of postmenopausal osteoporosis based on the data from a randomized, controlled phase III study that showed a significant reduction in the incidence of vertebral and nonvertebral fractures. Teriparatide is now also approved for the treatment of osteoporosis at high risk of fractures in men and glucocorticoid osteoporosis. The basis for these new indications were the positive results of randomized controlled studies in corresponding patient populations. | ||
| 653 | 0 | |a Osteopathy | |
| 773 | 0 | 8 | |i In |t Остеопороз и остеопатии |d Endocrinology Research Centre, 2018 |g 18(2015), 1, Seite 41-42 |w (DE-627)1760648779 |x 23110716 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2015 |g number:1 |g pages:41-42 |
| 856 | 4 | 0 | |u https://doi.org/10.14341/osteo2015141-42 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/da467b388c51405a9e05cf51e03dd59c |z kostenfrei |
| 856 | 4 | 0 | |u https://endojournals.ru/index.php/osteo/article/view/8904 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2072-2680 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2311-0716 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2015 |e 1 |h 41-42 | ||
| author_variant |
e a p eap |
|---|---|
| matchkey_str |
article:23110716:2015----::eiaaienotmoayramnootoooieiec |
| hierarchy_sort_str |
2015 |
| callnumber-subject-code |
RZ |
| publishDate |
2015 |
| allfields |
10.14341/osteo2015141-42 doi (DE-627)DOAJ003016064 (DE-599)DOAJda467b388c51405a9e05cf51e03dd59c DE-627 ger DE-627 rakwb eng rus RZ301-397.5 E A Pigarova verfasserin aut TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Osteoporosis - a disease witch relates to both women and men, present a growing global problem due to the aging population. Low bone mass and a deterioration microarchitecture are characteristic features of osteoporosis that can lead to fractures, related pain, physical disability, poor quality of life, increased mortality, and high costs of medical care. Teriparatide (recombinant human parathyroid hormone [rhPTH (1-34), Forsteo], which appeared more than a decade ago, is the only one registered in the Russian Federation anabolic treatment for osteoporosis, which increases the density and strength of bone. Initially, it was approved for the treatment of postmenopausal osteoporosis based on the data from a randomized, controlled phase III study that showed a significant reduction in the incidence of vertebral and nonvertebral fractures. Teriparatide is now also approved for the treatment of osteoporosis at high risk of fractures in men and glucocorticoid osteoporosis. The basis for these new indications were the positive results of randomized controlled studies in corresponding patient populations. Osteopathy In Остеопороз и остеопатии Endocrinology Research Centre, 2018 18(2015), 1, Seite 41-42 (DE-627)1760648779 23110716 nnns volume:18 year:2015 number:1 pages:41-42 https://doi.org/10.14341/osteo2015141-42 kostenfrei https://doaj.org/article/da467b388c51405a9e05cf51e03dd59c kostenfrei https://endojournals.ru/index.php/osteo/article/view/8904 kostenfrei https://doaj.org/toc/2072-2680 Journal toc kostenfrei https://doaj.org/toc/2311-0716 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 18 2015 1 41-42 |
| spelling |
10.14341/osteo2015141-42 doi (DE-627)DOAJ003016064 (DE-599)DOAJda467b388c51405a9e05cf51e03dd59c DE-627 ger DE-627 rakwb eng rus RZ301-397.5 E A Pigarova verfasserin aut TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Osteoporosis - a disease witch relates to both women and men, present a growing global problem due to the aging population. Low bone mass and a deterioration microarchitecture are characteristic features of osteoporosis that can lead to fractures, related pain, physical disability, poor quality of life, increased mortality, and high costs of medical care. Teriparatide (recombinant human parathyroid hormone [rhPTH (1-34), Forsteo], which appeared more than a decade ago, is the only one registered in the Russian Federation anabolic treatment for osteoporosis, which increases the density and strength of bone. Initially, it was approved for the treatment of postmenopausal osteoporosis based on the data from a randomized, controlled phase III study that showed a significant reduction in the incidence of vertebral and nonvertebral fractures. Teriparatide is now also approved for the treatment of osteoporosis at high risk of fractures in men and glucocorticoid osteoporosis. The basis for these new indications were the positive results of randomized controlled studies in corresponding patient populations. Osteopathy In Остеопороз и остеопатии Endocrinology Research Centre, 2018 18(2015), 1, Seite 41-42 (DE-627)1760648779 23110716 nnns volume:18 year:2015 number:1 pages:41-42 https://doi.org/10.14341/osteo2015141-42 kostenfrei https://doaj.org/article/da467b388c51405a9e05cf51e03dd59c kostenfrei https://endojournals.ru/index.php/osteo/article/view/8904 kostenfrei https://doaj.org/toc/2072-2680 Journal toc kostenfrei https://doaj.org/toc/2311-0716 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 18 2015 1 41-42 |
| allfields_unstemmed |
10.14341/osteo2015141-42 doi (DE-627)DOAJ003016064 (DE-599)DOAJda467b388c51405a9e05cf51e03dd59c DE-627 ger DE-627 rakwb eng rus RZ301-397.5 E A Pigarova verfasserin aut TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Osteoporosis - a disease witch relates to both women and men, present a growing global problem due to the aging population. Low bone mass and a deterioration microarchitecture are characteristic features of osteoporosis that can lead to fractures, related pain, physical disability, poor quality of life, increased mortality, and high costs of medical care. Teriparatide (recombinant human parathyroid hormone [rhPTH (1-34), Forsteo], which appeared more than a decade ago, is the only one registered in the Russian Federation anabolic treatment for osteoporosis, which increases the density and strength of bone. Initially, it was approved for the treatment of postmenopausal osteoporosis based on the data from a randomized, controlled phase III study that showed a significant reduction in the incidence of vertebral and nonvertebral fractures. Teriparatide is now also approved for the treatment of osteoporosis at high risk of fractures in men and glucocorticoid osteoporosis. The basis for these new indications were the positive results of randomized controlled studies in corresponding patient populations. Osteopathy In Остеопороз и остеопатии Endocrinology Research Centre, 2018 18(2015), 1, Seite 41-42 (DE-627)1760648779 23110716 nnns volume:18 year:2015 number:1 pages:41-42 https://doi.org/10.14341/osteo2015141-42 kostenfrei https://doaj.org/article/da467b388c51405a9e05cf51e03dd59c kostenfrei https://endojournals.ru/index.php/osteo/article/view/8904 kostenfrei https://doaj.org/toc/2072-2680 Journal toc kostenfrei https://doaj.org/toc/2311-0716 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 18 2015 1 41-42 |
| allfieldsGer |
10.14341/osteo2015141-42 doi (DE-627)DOAJ003016064 (DE-599)DOAJda467b388c51405a9e05cf51e03dd59c DE-627 ger DE-627 rakwb eng rus RZ301-397.5 E A Pigarova verfasserin aut TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Osteoporosis - a disease witch relates to both women and men, present a growing global problem due to the aging population. Low bone mass and a deterioration microarchitecture are characteristic features of osteoporosis that can lead to fractures, related pain, physical disability, poor quality of life, increased mortality, and high costs of medical care. Teriparatide (recombinant human parathyroid hormone [rhPTH (1-34), Forsteo], which appeared more than a decade ago, is the only one registered in the Russian Federation anabolic treatment for osteoporosis, which increases the density and strength of bone. Initially, it was approved for the treatment of postmenopausal osteoporosis based on the data from a randomized, controlled phase III study that showed a significant reduction in the incidence of vertebral and nonvertebral fractures. Teriparatide is now also approved for the treatment of osteoporosis at high risk of fractures in men and glucocorticoid osteoporosis. The basis for these new indications were the positive results of randomized controlled studies in corresponding patient populations. Osteopathy In Остеопороз и остеопатии Endocrinology Research Centre, 2018 18(2015), 1, Seite 41-42 (DE-627)1760648779 23110716 nnns volume:18 year:2015 number:1 pages:41-42 https://doi.org/10.14341/osteo2015141-42 kostenfrei https://doaj.org/article/da467b388c51405a9e05cf51e03dd59c kostenfrei https://endojournals.ru/index.php/osteo/article/view/8904 kostenfrei https://doaj.org/toc/2072-2680 Journal toc kostenfrei https://doaj.org/toc/2311-0716 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 18 2015 1 41-42 |
| allfieldsSound |
10.14341/osteo2015141-42 doi (DE-627)DOAJ003016064 (DE-599)DOAJda467b388c51405a9e05cf51e03dd59c DE-627 ger DE-627 rakwb eng rus RZ301-397.5 E A Pigarova verfasserin aut TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Osteoporosis - a disease witch relates to both women and men, present a growing global problem due to the aging population. Low bone mass and a deterioration microarchitecture are characteristic features of osteoporosis that can lead to fractures, related pain, physical disability, poor quality of life, increased mortality, and high costs of medical care. Teriparatide (recombinant human parathyroid hormone [rhPTH (1-34), Forsteo], which appeared more than a decade ago, is the only one registered in the Russian Federation anabolic treatment for osteoporosis, which increases the density and strength of bone. Initially, it was approved for the treatment of postmenopausal osteoporosis based on the data from a randomized, controlled phase III study that showed a significant reduction in the incidence of vertebral and nonvertebral fractures. Teriparatide is now also approved for the treatment of osteoporosis at high risk of fractures in men and glucocorticoid osteoporosis. The basis for these new indications were the positive results of randomized controlled studies in corresponding patient populations. Osteopathy In Остеопороз и остеопатии Endocrinology Research Centre, 2018 18(2015), 1, Seite 41-42 (DE-627)1760648779 23110716 nnns volume:18 year:2015 number:1 pages:41-42 https://doi.org/10.14341/osteo2015141-42 kostenfrei https://doaj.org/article/da467b388c51405a9e05cf51e03dd59c kostenfrei https://endojournals.ru/index.php/osteo/article/view/8904 kostenfrei https://doaj.org/toc/2072-2680 Journal toc kostenfrei https://doaj.org/toc/2311-0716 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 18 2015 1 41-42 |
| language |
English Russian |
| source |
In Остеопороз и остеопатии 18(2015), 1, Seite 41-42 volume:18 year:2015 number:1 pages:41-42 |
| sourceStr |
In Остеопороз и остеопатии 18(2015), 1, Seite 41-42 volume:18 year:2015 number:1 pages:41-42 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Osteopathy |
| isfreeaccess_bool |
true |
| container_title |
Остеопороз и остеопатии |
| authorswithroles_txt_mv |
E A Pigarova @@aut@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
1760648779 |
| id |
DOAJ003016064 |
| language_de |
englisch russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ003016064</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309172851.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.14341/osteo2015141-42</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ003016064</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJda467b388c51405a9e05cf51e03dd59c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RZ301-397.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">E A Pigarova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Osteoporosis - a disease witch relates to both women and men, present a growing global problem due to the aging population. Low bone mass and a deterioration microarchitecture are characteristic features of osteoporosis that can lead to fractures, related pain, physical disability, poor quality of life, increased mortality, and high costs of medical care. Teriparatide (recombinant human parathyroid hormone [rhPTH (1-34), Forsteo], which appeared more than a decade ago, is the only one registered in the Russian Federation anabolic treatment for osteoporosis, which increases the density and strength of bone. Initially, it was approved for the treatment of postmenopausal osteoporosis based on the data from a randomized, controlled phase III study that showed a significant reduction in the incidence of vertebral and nonvertebral fractures. Teriparatide is now also approved for the treatment of osteoporosis at high risk of fractures in men and glucocorticoid osteoporosis. The basis for these new indications were the positive results of randomized controlled studies in corresponding patient populations.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Osteopathy</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Остеопороз и остеопатии</subfield><subfield code="d">Endocrinology Research Centre, 2018</subfield><subfield code="g">18(2015), 1, Seite 41-42</subfield><subfield code="w">(DE-627)1760648779</subfield><subfield code="x">23110716</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:18</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:41-42</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.14341/osteo2015141-42</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/da467b388c51405a9e05cf51e03dd59c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://endojournals.ru/index.php/osteo/article/view/8904</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-2680</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2311-0716</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">18</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="h">41-42</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
E A Pigarova |
| spellingShingle |
E A Pigarova misc RZ301-397.5 misc Osteopathy TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS |
| authorStr |
E A Pigarova |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760648779 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RZ301-397 |
| illustrated |
Not Illustrated |
| issn |
23110716 |
| topic_title |
RZ301-397.5 TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS |
| topic |
misc RZ301-397.5 misc Osteopathy |
| topic_unstemmed |
misc RZ301-397.5 misc Osteopathy |
| topic_browse |
misc RZ301-397.5 misc Osteopathy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Остеопороз и остеопатии |
| hierarchy_parent_id |
1760648779 |
| hierarchy_top_title |
Остеопороз и остеопатии |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760648779 |
| title |
TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS |
| ctrlnum |
(DE-627)DOAJ003016064 (DE-599)DOAJda467b388c51405a9e05cf51e03dd59c |
| title_full |
TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS |
| author_sort |
E A Pigarova |
| journal |
Остеопороз и остеопатии |
| journalStr |
Остеопороз и остеопатии |
| callnumber-first-code |
R |
| lang_code |
eng rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
txt |
| container_start_page |
41 |
| author_browse |
E A Pigarova |
| container_volume |
18 |
| class |
RZ301-397.5 |
| format_se |
Elektronische Aufsätze |
| author-letter |
E A Pigarova |
| doi_str_mv |
10.14341/osteo2015141-42 |
| title_sort |
teriparatide in contemporary treatment of osteoporosis: evidence from recent publications |
| callnumber |
RZ301-397.5 |
| title_auth |
TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS |
| abstract |
Osteoporosis - a disease witch relates to both women and men, present a growing global problem due to the aging population. Low bone mass and a deterioration microarchitecture are characteristic features of osteoporosis that can lead to fractures, related pain, physical disability, poor quality of life, increased mortality, and high costs of medical care. Teriparatide (recombinant human parathyroid hormone [rhPTH (1-34), Forsteo], which appeared more than a decade ago, is the only one registered in the Russian Federation anabolic treatment for osteoporosis, which increases the density and strength of bone. Initially, it was approved for the treatment of postmenopausal osteoporosis based on the data from a randomized, controlled phase III study that showed a significant reduction in the incidence of vertebral and nonvertebral fractures. Teriparatide is now also approved for the treatment of osteoporosis at high risk of fractures in men and glucocorticoid osteoporosis. The basis for these new indications were the positive results of randomized controlled studies in corresponding patient populations. |
| abstractGer |
Osteoporosis - a disease witch relates to both women and men, present a growing global problem due to the aging population. Low bone mass and a deterioration microarchitecture are characteristic features of osteoporosis that can lead to fractures, related pain, physical disability, poor quality of life, increased mortality, and high costs of medical care. Teriparatide (recombinant human parathyroid hormone [rhPTH (1-34), Forsteo], which appeared more than a decade ago, is the only one registered in the Russian Federation anabolic treatment for osteoporosis, which increases the density and strength of bone. Initially, it was approved for the treatment of postmenopausal osteoporosis based on the data from a randomized, controlled phase III study that showed a significant reduction in the incidence of vertebral and nonvertebral fractures. Teriparatide is now also approved for the treatment of osteoporosis at high risk of fractures in men and glucocorticoid osteoporosis. The basis for these new indications were the positive results of randomized controlled studies in corresponding patient populations. |
| abstract_unstemmed |
Osteoporosis - a disease witch relates to both women and men, present a growing global problem due to the aging population. Low bone mass and a deterioration microarchitecture are characteristic features of osteoporosis that can lead to fractures, related pain, physical disability, poor quality of life, increased mortality, and high costs of medical care. Teriparatide (recombinant human parathyroid hormone [rhPTH (1-34), Forsteo], which appeared more than a decade ago, is the only one registered in the Russian Federation anabolic treatment for osteoporosis, which increases the density and strength of bone. Initially, it was approved for the treatment of postmenopausal osteoporosis based on the data from a randomized, controlled phase III study that showed a significant reduction in the incidence of vertebral and nonvertebral fractures. Teriparatide is now also approved for the treatment of osteoporosis at high risk of fractures in men and glucocorticoid osteoporosis. The basis for these new indications were the positive results of randomized controlled studies in corresponding patient populations. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
1 |
| title_short |
TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS |
| url |
https://doi.org/10.14341/osteo2015141-42 https://doaj.org/article/da467b388c51405a9e05cf51e03dd59c https://endojournals.ru/index.php/osteo/article/view/8904 https://doaj.org/toc/2072-2680 https://doaj.org/toc/2311-0716 |
| remote_bool |
true |
| ppnlink |
1760648779 |
| callnumber-subject |
RZ - Other Systems of Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.14341/osteo2015141-42 |
| callnumber-a |
RZ301-397.5 |
| up_date |
2024-07-03T15:28:03.070Z |
| _version_ |
1803572198056656896 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ003016064</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309172851.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.14341/osteo2015141-42</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ003016064</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJda467b388c51405a9e05cf51e03dd59c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RZ301-397.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">E A Pigarova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">TERIPARATIDE IN CONTEMPORARY TREATMENT OF OSTEOPOROSIS: EVIDENCE FROM RECENT PUBLICATIONS</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Osteoporosis - a disease witch relates to both women and men, present a growing global problem due to the aging population. Low bone mass and a deterioration microarchitecture are characteristic features of osteoporosis that can lead to fractures, related pain, physical disability, poor quality of life, increased mortality, and high costs of medical care. Teriparatide (recombinant human parathyroid hormone [rhPTH (1-34), Forsteo], which appeared more than a decade ago, is the only one registered in the Russian Federation anabolic treatment for osteoporosis, which increases the density and strength of bone. Initially, it was approved for the treatment of postmenopausal osteoporosis based on the data from a randomized, controlled phase III study that showed a significant reduction in the incidence of vertebral and nonvertebral fractures. Teriparatide is now also approved for the treatment of osteoporosis at high risk of fractures in men and glucocorticoid osteoporosis. The basis for these new indications were the positive results of randomized controlled studies in corresponding patient populations.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Osteopathy</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Остеопороз и остеопатии</subfield><subfield code="d">Endocrinology Research Centre, 2018</subfield><subfield code="g">18(2015), 1, Seite 41-42</subfield><subfield code="w">(DE-627)1760648779</subfield><subfield code="x">23110716</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:18</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:41-42</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.14341/osteo2015141-42</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/da467b388c51405a9e05cf51e03dd59c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://endojournals.ru/index.php/osteo/article/view/8904</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-2680</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2311-0716</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">18</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="h">41-42</subfield></datafield></record></collection>
|
| score |
7.399109 |